Country: Malta
Language: English
Source: Medicines Authority
BIMATOPROST
Sandoz Limited 200 Frimley Business Park, Frimley Camberley, Surrey GU16 7SR, United Kingdom
S01EE03
BIMATOPROST 0.3 mg/ml
EYE DROPS, SOLUTION
BIMATOPROST 0.3 mg/ml
POM
OPHTHALMOLOGICALS
Withdrawn
2014-02-27
1 PACKAGE LEAFLET: INFORMATION FOR THE USER BIMATOPROST 0.3 MG/ML EYE DROPS, SOLUTION Bimatoprost READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What BIMATOPROST 0.3 mg/ml is and what it is used for 2. What you need to know before you use BIMATOPROST 0.3 mg/ml 3. How to use BIMATOPROST 0.3 mg/ml 4. Possible side effects 5. How to store BIMATOPROST 0.3 mg/ml 6. Contents of the pack and other information 1. WHAT BIMATOPROST 0.3 MG/ML IS AND WHAT IT IS USED FOR BIMATOPROST is an antiglaucoma preparation. It belongs to a group of medicines called prostamides. BIMATOPROST is used to reduce high pressure in the eye. This medicine may be used on its own or with other drops called beta-blockers which also reduce pressure. Your eye contains a clear, watery liquid that feeds the inside of the eye. Liquid is constantly being drained out of the eye and new liquid is made to replace this. If the liquid cannot drain out quickly enough, the pressure inside the eye builds up. This medicine works by increasing the amount of liquid that is drained. This reduces the pressure inside the eye. If the high pressure is not reduced, it could lead to a disease called glaucoma and eventually damage your sight. 2. WHAT Read the complete document
Page 1 of 12 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Cluvot 250 IU, powder and solvent for solution for injection/infusion. Cluvot 1250 IU, powder and solvent for solution for injection/infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Cluvot is a purified concentrate of human plasma coagulation factor XIII (FXIII). It is presented as a white powder. Each vial contains nominally 250 or 1250 IU human plasma coagulation factor XIII. Cluvot contains approximately 62.5 IU/ml (250 IU/4 ml and 1250 IU/20 ml) of human plasma coagulation factor XIII when reconstituted with 4 and 20 ml water for injection, respectively. The specific activity of Cluvot is approximately 6 – 10 IU/mg protein. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection/ infusion. White powder and clear, colourless solvent. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cluvot is indicated for adult and paediatric patients • for prophylactic treatment of congenital FXIII deficiency and • for peri-operative management of surgical bleeding with congenital FXIII deficiency. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _POSOLOGY _ 1 ml is equivalent to approximately 62.5 IU, and 100 IU are equivalent to 1.6 ml, respectively. Important: The amount to be administered and the frequency of administration should always be oriented towards the clinical efficacy in the individual case. _DOSAGE _ The dosing regimen should be indi Read the complete document